Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996614 | 0.89 | SCNN1A (0.75) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015164 | 0.86 | SCNN1A (1.00) | SCNN1A | |
| SCHEMBL916348 | 0.83 | SCNN1A (0.94) | SCNN1A | |
| 552-02 Free Base SCHEMBL15092803 | 0.81 | SCNN1A (0.67) | SCNN1A | |
| 552-02 Free Base SCHEMBL29615808 | 0.81 | SCNN1A (0.67) | SCNN1A | |
| SCHEMBL16499025 | 0.80 | SCNN1A (0.70) | SCNN1A | |
| SCHEMBL16499028 | 0.80 | SCNN1A (0.70) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015162 | 0.78 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913774 | 0.78 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913757 | 0.78 | SCNN1A (0.71) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2025-07-29 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2024-02-29 | — | — | US | disclosed |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | Enterprise Therapeutics Limited (GB) | 2023-08-29 | — | — | US | disclosed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210188855-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2021-06-24 | — | — | US | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | Enterprise Therapeutics Limited (GB) | 2021-05-20 | — | — | US | disclosed |
| EP-2855435-A2 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | Parion Sciences, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140336159-A1 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS | PULMATRIX, INC. | 2014-11-13 | — | — | US | disclosed |
| WO-2014099705-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | PARION SCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140107133-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | PARION SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8669262-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | PARION SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2013181232-A2 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | JOHNSON MICHAEL ROSS (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130178482-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | PARION SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336159-A1 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS | TLR3, TLR1, TLR4 | SCNN1A 593/4885 |
| US-11739094-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20140170244-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS | CFTR, SCNN1B, SCN5A | SCNN1A 4/4885 |
| US-12371436-B2 | Substituted benzodiazoliums as ENaC inhibitors | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20140107133-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | CFTR, ELANE, IL5 | SCNN1A 314/4885 |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | SCNN1B, SCNN1A, SCNN1G | SCNN1A 2/4885 |
| US-20240067653-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-11578042-B2 | 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide | CFTR, ELANE, IL5 | SCNN1A 314/4885 |
| US-20130178482-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE | CFTR, ELANE, IL5 | SCNN1A 314/4885 |
| US-20210147432-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20210188855-A1 | COMPOUNDS | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20130324559-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | SCNN1A 2/4885 |
| US-20250304590-A1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | NHERF1, SCNN1B, SCNN1A | SCNN1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.